Featured Research

from universities, journals, and other organizations

Explaining 'healthy' obesity

Date:
July 3, 2014
Source:
Cell Press
Summary:
Up to one-quarter of individuals currently labeled as obese are actually metabolically healthy. Though obesity is a major risk factor for diabetes, the two conditions aren't always linked. A new study sheds light on a possible explanation, revealing that high levels of a molecule HO-1 are linked to poor metabolic health and an increased risk of type 2 diabetes in obese humans. HO-1 blockers could represent a promising new strategy for the treatment of metabolic disease.

Up to one-quarter of individuals currently labeled as obese are actually metabolically healthy and do not have a high risk of developing type 2 diabetes. Though obesity is a major risk factor for diabetes, the two conditions aren't always linked. A study published by Cell Press July 3rd in the journal Cell sheds light on a possible explanation, revealing that high levels of a molecule called heme oxygenase-1 (HO-1) are linked to poor metabolic health and an increased risk of type 2 diabetes in obese humans. Moreover, HO-1 inhibition improves metabolic health in obese mice, suggesting that HO-1 blockers could represent a promising new strategy for the treatment of metabolic disease.

"The results indicate that HO-1 is in fact necessary for the development of metabolic disease and call for a re-evaluation of numerous findings in the field," says senior study author Harald Esterbauer of the Medical University of Vienna. "The study also reveals HO-1 as a candidate biomarker for the stratification of metabolically healthy and unhealthy obesity and provides a framework for selective, personalized therapy."

The factors that determine whether obesity leads to poor metabolic health have been unclear, but the evidence suggests that a maladaptive immune response called metabolic inflammation plays an important role. However, studies examining the relationship between a supposedly anti-inflammatory molecule called HO-1 and metabolic disease have produced conflicting results.

To address this question, Esterbauer teamed up with senior study author J. Andrew Pospisilik of the Max Planck Institute of Immunobiology and Epigenetics. In contrast to past findings, they found higher levels of HO-1 in liver and fat biopsies from obese, insulin-resistant humans compared with obese, metabolically healthy individuals. When the researchers deleted the HO-1 gene in immune cells called macrophages, molecular signs of inflammation decreased in mice, suggesting that HO-1 actually promotes inflammation, contrary to widespread belief. Moreover, deletion of the HO-1 gene specifically in the liver or macrophages of mice fed a high-fat diet led to better liver function and an increase in insulin sensitivity -- a clear sign of improved metabolic health.

"Our findings show that HO-1 is among the strongest predictors of metabolically unhealthy obesity in humans, and it could have a high prognostic value for detecting disease onset," Pospisilik says. "This could allow clinicians to use targeted interventions to prevent disease progression specifically in obese individuals who show early signs of type 2 diabetes."


Story Source:

The above story is based on materials provided by Cell Press. Note: Materials may be edited for content and length.


Journal Reference:

  1. Alexander Jais, Elisa Einwallner, Omar Sharif, Klaus Gossens, Tess Tsai-Hsiu Lu, Selma M. Soyal, David Medgyesi, Daniel Neureiter, Jamile Paier-Pourani, Kevin Dalgaard, J. Catharina Duvigneau, Josefine Lindroos-Christensen, Thea-Christin Zapf, Sabine Amann, Simona Saluzzo, Florian Jantscher, Patricia Stiedl, Jelena Todoric, Rui Martins, Hannes Oberkofler, Simone Müller, Cornelia Hauser-Kronberger, Lukas Kenner, Emilio Casanova, Hedwig Sutterlüty-Fall, Martin Bilban, Karl Miller, Andrey V. Kozlov, Franz Krempler, Sylvia Knapp, Carey N. Lumeng, Wolfgang Patsch, Oswald Wagner, J. Andrew Pospisilik, Harald Esterbauer. Heme Oxygenase-1 Drives Metaflammation and Insulin Resistance in Mouse and Man. Cell, 2014; 158 (1): 25 DOI: 10.1016/j.cell.2014.04.043

Cite This Page:

Cell Press. "Explaining 'healthy' obesity." ScienceDaily. ScienceDaily, 3 July 2014. <www.sciencedaily.com/releases/2014/07/140703125528.htm>.
Cell Press. (2014, July 3). Explaining 'healthy' obesity. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2014/07/140703125528.htm
Cell Press. "Explaining 'healthy' obesity." ScienceDaily. www.sciencedaily.com/releases/2014/07/140703125528.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) — Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) — The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) — Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) — New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins